Using one previously described set of criteria for PSMA RLT in prostate cancer [21] (lesion PSMA uptake greater than or equal to liver background, and no discordant PSMA negative/FDG positive lesions), 8/11 patients in our cohort could be eligible for PSMA RLT. Here, FOLH1 is linked to prostate carcinoma.